Want to see TSE:ZEN full AI Analyst Report?
Top Page
Zentek
(ZEN)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.71
▼(-7.79% Downside)
Action:Reiterated
Date:08/26/26
The score is held back primarily by weak financial performance—minimal and declining revenue, persistent losses, and ongoing cash burn. Technical indicators are broadly neutral and do not strongly offset the fundamentals. Corporate developments are positive (federal standing offer and new patent filing), but their current scale does not yet meaningfully change the near-term financial risk profile.
Positive Factors
Low Financial Leverage
Modest leverage and meaningful equity provide Zentek with a financial cushion while it continues investing in technology and commercialization. Lower debt exposure reduces refinancing and solvency pressure, preserving greater flexibility to fund development despite current operating losses.
Negative Factors
Very Small and Declining Revenue
Extremely low and declining revenue indicates that Zentek has not yet established durable commercial scale. Limited sales reduce internal funding capacity, make fixed research and corporate costs harder to absorb, and leave the company dependent on future product adoption or partner commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Modest leverage and meaningful equity provide Zentek with a financial cushion while it continues investing in technology and commercialization. Lower debt exposure reduces refinancing and solvency pressure, preserving greater flexibility to fund development despite current operating losses.
Read all positive factors
Zentek (ZEN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$92.43M
Dividend YieldN/A
Average Volume (3M)122.87K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth-88.29%
EPS Growth-13.25%
CountryCA
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume116,535
30 Day Avg. Volume122,872
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zentek Business Overview & Revenue Model
Company Description
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coatin...
How the Company Makes Money
Zentek’s monetization is based on commercializing its materials technologies rather than operating as a traditional commodity producer. In general terms, the company can generate revenue through (1) direct sales of products derived from its materi...
Zentek Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 108.25K | 166.05K | 872.50K | 29.82K | 72.86K | 339.67K |
| Gross Profit | -5.43M | -6.29M | 192.49K | -385.06K | -780.48K | -275.04K |
| EBITDA | -10.59M | -10.30M | -9.35M | -11.08M | -13.75M | -11.27M |
| Net Income | -10.45M | -9.77M | -10.04M | -11.70M | -14.41M | -38.69M |
Balance Sheet | ||||||
| Total Assets | 30.86M | 15.09M | 18.40M | 22.59M | 33.29M | 37.98M |
| Cash, Cash Equivalents and Short-Term Investments | 16.60M | 1.30M | 121.48K | 3.52M | 10.36M | 26.68M |
| Total Debt | 1.93M | 1.91M | 680.47K | 1.24M | 1.61M | 2.23M |
| Total Liabilities | 5.60M | 5.28M | 3.65M | 2.41M | 2.90M | 3.44M |
| Stockholders Equity | 25.26M | 9.80M | 14.75M | 20.17M | 30.38M | 34.55M |
Cash Flow | ||||||
| Free Cash Flow | -5.57M | -5.77M | -6.28M | -8.37M | -15.23M | -11.97M |
| Operating Cash Flow | -5.07M | -5.07M | -6.28M | -8.05M | -12.96M | -7.99M |
| Investing Cash Flow | -1.23M | 1.67M | 358.65K | 1.88M | -2.31M | -7.25M |
| Financing Cash Flow | 20.01M | 4.58M | 2.52M | -665.47K | -1.05M | 38.82M |
Zentek Technical Analysis
Negative
0.77
Price Trends
0.77
Negative
0.76
Negative
0.85
Negative
Market Momentum
-0.02
Positive
41.15
Neutral
58.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZEN, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.77, and below the 200-day MA of 0.85, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 41.15 is Neutral, neither overbought nor oversold. The STOCH value of 58.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZEN.
Zentek Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | C$159.64M | -47.15 | -4.72% | ― | -3.16% | -345.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$92.43M | -7.58 | -70.73% | ― | -88.29% | -13.25% | |
49 Neutral | C$40.03M | -14.67 | 1894.66% | ― | ― | 14.18% | |
44 Neutral | C$65.22M | -21.41 | 74.79% | ― | ― | -15.53% | |
42 Neutral | C$52.18M | -35.56 | -250.77% | ― | -82.05% | 23.73% |
* Healthcare Sector Average
TSE:ZEN
Zentek
0.71
-0.74
-51.03%
TSE:ARCH
Arch Biopartners
0.91
-0.76
-45.51%
TSE:BUX
BioMark Diagnostics
0.48
0.11
31.51%
TSE:MDP
Medexus Pharmaceuticals Inc
5.01
1.91
61.61%
TSE:SONA
Sona Nanotech Inc
0.36
-0.24
-39.83%
Zentek Corporate Events
Delistings and Listing Changes
Zentek Shifts U.S. Trading to OTCQX as Nasdaq Listing Suspended
Neutral
Sep 1, 2026
Zentek Ltd., a Canadian IP development and commercialization firm, specializes in graphene-enabled and advanced material technologies serving clean air applications, next-generation materials, and critical minerals markets. The company’s pri...
Business Operations and StrategyDelistings and Listing Changes
Zentek Clarifies OTC Debut Date and Outlines U.S. Trading Transition
Neutral
Aug 31, 2026
Zentek Ltd. corrected a previous disclosure on its U.S. trading plans, clarifying that its common shares are expected to begin quotation on the OTC Markets at the open of trading on Wednesday, September 2, 2026, rather than on a Tuesday as earlier...
Delistings and Listing ChangesRegulatory Filings and Compliance
Zentek Shares to Shift From Nasdaq to OTC Markets After Delisting Notice
Negative
Aug 28, 2026
Zentek Ltd. said its common shares will move from the Nasdaq Capital Market to the OTC Markets Group on September 2, 2026, after receiving a delisting notice tied to non-compliance with Nasdaq’s minimum bid price requirement. Trading on Nasd...
Business Operations and StrategyProduct-Related Announcements
Zentek Wins Ottawa HVAC Filter Deal as ZenGUARD Gains Federal Traction
Positive
Aug 20, 2026
Zentek Ltd., a Canadian IP development company, is commercializing graphene-enabled and advanced material technologies across clean air, next-generation materials, and critical minerals, anchored by its Albany graphite, ZenGUARD™, and Triera...
Business Operations and StrategyProduct-Related Announcements
Zentek Files Patent for Albany-Graphite EMI Shielding Coating
Positive
Aug 17, 2026
Zentek has filed a provisional U.S. patent application for ZEN-EMI-01, a water-based electromagnetic interference shielding coating derived from purified graphite from its Albany deposit. The coating is designed to absorb electromagnetic energy as...
Product-Related AnnouncementsRegulatory Filings and Compliance
CI Global Asset Management Lowers Risk Ratings on Three Funds, Raises One
Neutral
Jul 16, 2026
CI Global Asset Management has adjusted the risk ratings on four of its mutual funds and corresponding ETFs, shifting three alternative strategies and a global climate-focused fund into lower or higher risk bands. The CI Alternative Diversified Op...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.